# Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Study · id `cardio:ct-nct05084118` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05084118](<https://clinicaltrials.gov/study/NCT05084118>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05084118

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 164 participants.

## Technical summary

Registry record NCT05084118. Randomized; quadruple masking; primary purpose prevention. Start 2021-10-21 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 164 participants (planned count; ClinicalTrials.gov record NCT05084118, source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)
- Started: 2021-10-21 (actual) (ClinicalTrials.gov record NCT05084118, source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)
- Primary completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT05084118, source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)
- Completion: 2024-06-01 (anticipated) (ClinicalTrials.gov record NCT05084118, source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)
- Countries: Austria (ClinicalTrials.gov record NCT05084118, source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05084118-2021-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
- Acronym: LANDI-POAF
- Condition: Atrial Fibrillation
- Condition: Postoperative Complications
- Intervention (Drug): Landiolol HCl
- Intervention (Drug): Placebo
- Lead sponsor: Medical University of Vienna
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Medical University of Vienna (`cardio:org-medical-university-of-vienna`)

## Provenance

Content hash: b87eb8cc6ed3097cd7915a9daea7d18f7c216510a9698bcf35004bcb85be21e2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
